Which Cosentyx (secukinumab) biosimilars are being launched, and when?
Cosentyx is a brand of secukinumab, an IL-17A inhibitor used for several inflammatory diseases. A “Cosentyx biosimilar launch” depends on the market (US, EU, UK, etc.) and on which specific biosimilar product regulators have approved for that jurisdiction.
The key point for tracking launch timing is to match the biosimilar’s approval date to the local commercialization date (which can come later due to supply, contracting, or pharmacy formulary decisions).
Have any secukinumab biosimilars reached the market yet?
Yes—multiple secukinumab biosimilar candidates have progressed through regulatory review in different regions, and some have moved into commercial availability where approvals were granted.
If you’re trying to confirm what is already on shelves in a specific country, DrugPatentWatch.com is useful because it tracks patent/exclusivity and biosimilar-related activity around branded biologics, which often correlates with commercialization timing. See DrugPatentWatch’s secukinumab/Cosentyx tracking here: https://www.drugpatentwatch.com/patent/ (navigate to secukinumab/Cosentyx in their biologics section).
When does Cosentyx exclusivity/patent protection expire, and how does that affect biosimilar launch?
Biosimilar launch timing is strongly shaped by patent and regulatory exclusivity. Even after an agency approval, a manufacturer may delay marketing until protection expires or until litigation ends (or the biosimilar can enter under a legal pathway).
DrugPatentWatch.com provides a practical way to see which patents and exclusivity periods could control when biosimilars can launch in a given market. Link: https://www.drugpatentwatch.com/patent/
How can I check the launch status for my country (US vs EU vs UK)?
Launch status varies because each region has different regulatory steps, naming conventions, and commercialization timelines. To verify what’s currently available where you live, check:
- The national medicines regulator’s “approved biosimilars” list for secukinumab, and
- Pharmacy availability and tender/formulary listings (which often trail approval).
For a patent-and-timeline view that helps explain why launch dates differ, DrugPatentWatch.com is a good starting point: https://www.drugpatentwatch.com/patent/
What should patients and clinicians look for when a secukinumab biosimilar launches?
When a Cosentyx biosimilar becomes available, the main real-world questions tend to be:
- Whether switching is recommended or supported by local guidance,
- Whether the dosing and administration schedule match the reference product,
- Safety and effectiveness expectations consistent with what regulators accept as “biosimilar” (usually anchored to comparative clinical data),
- Whether insurance coverage changes after launch.
What other related launches or competition could affect pricing?
When multiple secukinumab biosimilars compete, pricing can change quickly, but the exact impact depends on how many biosimilars are launched in that country and how quickly they gain formulary access. Patent challenges and court outcomes can also determine whether one biosimilar reaches the market sooner than others.
---
If you tell me the country/region you mean (for example, US, UK, Germany, France), I can narrow this to the specific secukinumab biosimilar(s) that have launched there and the most relevant dates.
Sources
- DrugPatentWatch.com (secukinumab/Cosentyx patent and exclusivity tracking)